At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21 enrolled
Drug / intervention
Azilsartan medoximil +1 moredrug
Likely dose
Azilsartan medoximil 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Azilsartan on Aldosterone in Postmenopausal Females
In Brief
A clinical study evaluating Azilsartan medoximil and Placebo for Hypertension. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The purpose of the research is to evaluate the effect of azilsartan medoximil on blood pressure and urinary aldosterone levels in postmenopausal females.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
CollaboratorsTakeda
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionNov 2015
Study CompletionJan 2016
TodayJul 2026
First PostedJan 24, 2013
Enrollment StartJan 1, 2013
Primary CompletionNov 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.4 years ago
Interventions
Azilsartan medoximildrug
All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
Placebodrug
All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.